# EDGAR Filing Document

**Accession Number:** 0001661998
**File Stem:** 0001193125-25-146179
**Filing Date:** 2025-6
**Character Count:** 13682
**Document Hash:** fae18906cb1db956bdee43639fe39485
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-146179.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001193125-25-146179

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250620

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q32 Bio Inc.
- **CENTRAL INDEX KEY:** 0001661998
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473468154
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38433
- **FILM NUMBER:** 251071047

**BUSINESS ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 781-999-0232

**MAIL ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Homology Medicines, Inc.
- **DATE OF NAME CHANGE:** 20151228

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 20, 2025

## Q32 Bio Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38433** | **47-3468154** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |
| **830 Winter Street** | **830 Winter Street** |  |
| **Waltham, Massachusetts** | **Waltham, Massachusetts** | **02451** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: 781 999-0232

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common stock, par value $0.0001 per share | QTTB | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

On June 20, 2025, Jason Campagna, M.D., Ph.D. resigned from his role as Chief Medical Officer of Q32 Bio Inc. (the "Company"), effective as of July 9, 2025. Adrien Sipos, M.D., Ph.D. has been appointed by the Company as its Interim Chief Medical Officer, effective as of July 9, 2025.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

On June 25, 2025, the Company issued a press release announcing the foregoing leadership transition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 99.1 | [Press Release issued on June 25, 2025.](d917821dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **Q32 BIO INC.** |
| Date: June 25, 2025 | By: | /s/ Jodie Morrison |
|  | Name:<br> Title: | Jodie Morrison <br>Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g917821g0625032502159.jpg)

**Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer** 

*— Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience —* 

**WALTHAM, Mass.—June 25, 2025** – Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company.

"Adrien has a proven track record of success in roles that span clinical development and medical affairs supporting commercial launches. She brings deep I&I expertise that will be invaluable as we advance bempikibart in the ongoing Part B and open-label extension portions of the SIGNAL-AA Phase 2a clinical trial in patients with alopecia areata. We are thrilled to welcome Adrien to the team," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We would also like to thank Jason for his contributions to Q32 Bio and for his role advancing bempikibart into Phase 2 clinical development."

"It's an exciting time to join Q32 Bio as we advance the SIGNAL-AA Phase 2a clinical trial and approach topline results from the Part B portion in the first half of next year. Bempikibart, a fully human anti-IL-7Rα antibody that blocks IL-7 and TSLP signaling, is a novel approach to treating alopecia areata and clinical data to date show promising potential for patients in need of new treatment options," said Dr. Sipos. "I look forward to helping Q32 Bio advance bempikibart and have a meaningful impact for patients living with alopecia areata and other autoimmune and inflammatory diseases."

Prior to joining Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc., where she advised both large and emerging biopharmaceutical companies on clinical development and medical affairs initiatives across multiple therapeutic areas and development stages. Prior to PRAXICO, Dr. Sipos was Head of Immunology, Late-Stage Clinical Development at Biogen, Inc., where she established the global clinical development organization for late-stage immunology and oversaw development and regulatory activities for multiple mid- to late-stage programs. Earlier, Dr. Sipos held clinical development and medical affairs roles of increasing responsibility, with an emphasis on immunology, at Sanofi Genzyme and Eli Lilly. Dr. Sipos completed postdoctoral research at the University of Oxford, Linacre College, and received a Ph.D. in Clinical Immunology from the Hungarian Academy of Sciences. She received an M.D. and completed her medical residency at Debrecen Medical University specializing in clinical immunology and endocrine care. Dr. Sipos is a member of the Beth Israel Deaconess Medical Center's Institutional Biosafety Committee.

------

![LOGO](g917821g0625032502159.jpg)

**About Q32 Bio** 

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata<sup>1</sup>, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

<sup>1</sup> National Alopecia Areata Foundation

**Availability of Other Information About Q32 Bio** 

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

**Forward-Looking Statements** 

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements, including, among others, Q32 Bio's beliefs, observations, expectations and assumptions regarding the data reported to date from Part A of the SIGNAL-AA Phase 2a clinical trial, the plan, purpose and timing of Part B of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its data, the safety, tolerability, clinical activity, durability, potential efficacy and potential benefits of bempikibart, and Q32 Bio's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including the leadership transition, which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies, including Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed by the first half of 2026 or at all, might be more costly than expected or might not yield anticipated results, the risk that Q32 Bio may

------

![LOGO](g917821g0625032502159.jpg)

use its capital resources sooner than currently anticipated and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

**Contacts:** 

Investors: Brendan Burns

Argot Partners

212.600.1902 Q32Bio@argotpartners.com

Media: David Rosen

Argot Partners

646.461.6387 david.rosen@argotpartners.com